Form 4: KKR Genetic Disorder L.P. Sells 5.8 Million Shares of BridgeBio Pharma
SEC Form 4
KKR Genetic Disorder L.P. sold 5.8 million shares of BridgeBio Pharma at $25.75 per share on September 13, 2024.
Summary
- KKR Genetic Disorder L.P. sold 5,800,000 shares of BridgeBio Pharma, Inc. common stock on September 13, 2024.
- The sale price was $25.75 per share.
- The transaction was executed pursuant to Rule 144 of the Securities Act of 1933.
- Following the transaction, KKR Genetic Disorder L.P. indirectly holds 25,260,971 shares of BridgeBio Pharma, Inc.
- Multiple entities and individuals related to KKR disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a transaction without expressing positive or negative views on the company's prospects.
Industry Context
This transaction represents a significant block trade by a major shareholder, KKR, in a publicly traded biotechnology company. Such sales can influence market sentiment and stock price, particularly when executed by well-known investment firms.
Stakeholder Impact
- The sale of a large block of shares could potentially impact the stock price and investor confidence in BridgeBio Pharma.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of transaction: sale of 5,800,000 shares of BBIO common stock. |
| 09/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.